{"product_id":"biolegend-130207","title":"Biolegend, 130207, PE anti-mouse CD314 (NKG2D) Antibody, 50μg","description":"\u003cp\u003eThis antibody has been reported to block binding of NKG2D to its ligands, RAE-1 and H60, and inhibition of NKG2D-dependent NK-cell cytotoxicity.\u003cbr\u003e\n50μg\u003cbr\u003e\nVerified Reactivity: Mouse\u003cbr\u003e\nAntibody Type: Monoclonal\u003cbr\u003e\nHost Species: Rat\u003cbr\u003e\nImmunogen: Mouse NKG2D\u003cbr\u003e\nFormulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.\u003cbr\u003e\nPreparation: The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions.\u003cbr\u003e\nConcentration: 0.2 mg\/ml\u003cbr\u003e\nStorage \u0026amp; Handling: The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.\u003cbr\u003e\nApplication: FC - Quality tested\u003cbr\u003e\nRecommended Usage: Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.25 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.\u003cbr\u003e\nExcitation Laser: Blue Laser (488 nm)Green Laser (532 nm)\/Yellow-Green Laser (561 nm)\u003cbr\u003e\nApplication Notes: To reduce non-specific binding, preincubate cells with purified anti-mouse CD16\/CD32, clone 93 (Cat No 101301\/2) is recommended. This product is for in vitro research use only. It is not to be used for commercial purposes. Use of this product to produce products for sale or for diagnostic therapeutic or drug discovery purposes is prohibited. In order to obtain a license to use this product for commercial purposes contact The Regents of the University of California.\u003cbr\u003e\nApplication References(PubMed link indicates BioLegend citation): Ogasawara K, et al. 2003. Immunity 18:41. (Block) Ogasawara K, et al. 2004. Immunity 20:757. (Block) Kong LY, et al. 2010. Clin. Cancer Res. 16:2550. PubMed\u003cbr\u003e\nProduct Citations: Calabrese DR, et al. 2020. J Clin Invest. . PubMed Davies AJ et al. 2019. Cell. 176(4):716-728 . PubMed Aghayev T, et al. 2022. Cancer Discov. 12:1960. PubMed Lin YH 2023. Immunity. 56(1):207-223.e8. PubMed Ren Z, et al. 2021. EMBO Molecular Medicine. :e14059. PubMed Barsoumian HB, et al. 2020. J Immunother Cancer. 8:00. PubMed Marcus A et al. 2018. Immunity. 49(4):754-763 . PubMed Kong L, et al. 2010. Clin Cancer Res. 2.4375. PubMed Patil ND, et al. 2022. Front Immunol. 13:818015. PubMed\u003cbr\u003e\nRRID: AB_1227713 (BioLegend Cat. No. 130207) AB_1227712 (BioLegend Cat. No. 130208)\u003cbr\u003e\nStructure: NKG2D is a lectin-like type II transmembrane protein. It serves as a stimulatory receptor to activate NK cells via the non-covalently associated DAP10 or DAP 12 daptor protein.\u003cbr\u003e\nDistribution: NK, NKT cells\u003cbr\u003e\nLigand\/Receptor: RAE, H60,\u003cbr\u003e\nCell Type: NK cells, NKT cells\u003cbr\u003e\nBiology Area: Costimulatory Molecules, Immunology\u003cbr\u003e\nMolecular Family: CD Molecules\u003cbr\u003e\nGene ID: 27007\u003cbr\u003e\nUniProt: View information about CD314 on UniProt.org\u003cbr\u003e\nClone: CX5\u003cbr\u003e\nRegulatory Status: RUO\u003cbr\u003e\nOther Names: CD314\u003cbr\u003e\nIsotype: Rat IgG1, κ\u003cbr\u003e\nQ: What type of PE do you use in your conjugates?\u003cbr\u003e\nA: We use R-PE in our conjugates.\u003c\/p\u003e","brand":"Biolegend","offers":[{"title":"Default Title","offer_id":46862996635817,"sku":"130207","price":0.99,"currency_code":"USD","in_stock":true}],"url":"https:\/\/iright.com\/ar\/products\/biolegend-130207","provider":"Iright","version":"1.0","type":"link"}